Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion

Background Changes in anemia management practices due to concerns about erythropoiesis-stimulating agent safety and Medicare payment changes may increase patient risk of transfusion. We examined anemia management trends in hemodialysis patients and risk of red blood cell (RBC) transfusion according...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of kidney diseases 2014-06, Vol.63 (6), p.997-1006
Hauptverfasser: Collins, Allan J., MD, Monda, Keri L., PhD, Molony, Julia T., MS, Li, Suying, PhD, Gilbertson, David T., PhD, Bradbury, Brian D., DSc
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1006
container_issue 6
container_start_page 997
container_title American journal of kidney diseases
container_volume 63
creator Collins, Allan J., MD
Monda, Keri L., PhD
Molony, Julia T., MS
Li, Suying, PhD
Gilbertson, David T., PhD
Bradbury, Brian D., DSc
description Background Changes in anemia management practices due to concerns about erythropoiesis-stimulating agent safety and Medicare payment changes may increase patient risk of transfusion. We examined anemia management trends in hemodialysis patients and risk of red blood cell (RBC) transfusion according to dialysis facility–level hemoglobin concentration. Study Design Retrospective follow-up study; 6-month study period (January to June), 3-month exposure/follow-up. Setting & Participants For each year in 2007-2011, annual cohorts of point-prevalent Medicare primary payer patients receiving hemodialysis on January 1 with one or more hemoglobin measurements during the study period. Annual cohorts averaged 170,000 patients, with 130,000 patients and 3,100 facilities for the risk analysis. Predictor Percentage of facility patient-months with hemoglobin level < 10 g/dL. Outcome Patient-level RBC transfusion rates. Measurements Monthly epoetin alfa and intravenous iron doses, mean hemoglobin levels, and RBC transfusion rates; percentage of facility patient-months with hemoglobin levels < 10 g/dL (exposure) and patient-level RBC transfusion rates (follow-up). Results Percentages of patients with hemoglobin levels < 10 g/dL increased every year from 2007 (6%) to 2011 (∼11%). Epoetin alfa doses, iron doses, and transfusion rates remained relatively stable through 2010 and changed in 2011. Median monthly epoetin alfa and iron doses decreased 25% and 43.8%, respectively, and monthly transfusion rates increased from 2.8% to 3.2% in 2011, a 14.3% increase. Patients in facilities with the highest prevalence of hemoglobin levels < 10 g/dL over 3 months were at ∼30% elevated risk of receiving RBC transfusions within the next 3 months (relative risk, 1.28; 95% CI, 1.22-1.34). Limitations Possibly incomplete claims data; smaller units excluded; hemoglobin levels reported monthly for patients receiving epoetin alfa; transfusions usually not administered in dialysis units. Conclusions Dialysis facility treatment practices, as assessed by percentage of patient-months with hemoglobin levels < 10 g/dL over 3 months, were associated significantly with risk of transfusions in the next 3 months for all patients in the facility, regardless of patient case-mix.
doi_str_mv 10.1053/j.ajkd.2013.10.052
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1528885231</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638613014352</els_id><sourcerecordid>1528885231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-bf74f9bd9f96f6bf396d9c42b293dcad5e6ccb296396d6395bb38e0f235311d33</originalsourceid><addsrcrecordid>eNp9kUuLFDEQgIMo7rj6BzxIXwQvPeYxSadBBBl3XWFA0fXgKaTzkPT0dNZU98L8e6uZUcGDEBJS9VUlfEXIc0bXjErxul_bfu_XnDKBgTWV_AFZMclFrbTQD8mK8obXSmh1QZ4A9JTSVij1mFzwjWCyaeiKfL-KMbipyrG6ti4NaTrWu3AfhuomHPKPIXdprLZ5dGGcip1SHitc75MdjpCg-owhzFRfEuyXHrfFjhBnQO4peRTtAOHZ-bwk366vbrc39e7Th4_bd7vaSdpMdRebTWw738ZWRdVF0Srfug3veCu8s14G5Rxe1JLATXad0IFGLqRgzAtxSV6d-t6V_HMOMJlDAheGwY4hz2BQiNYarTBE-Ql1JQOUEM1dSQdbjoZRsyg1vVmUmkXpEkOlWPTi3H_uDsH_KfntEIGXZ8CCs0NEBS7BX05LoRvZIPfmxAW0cZ9CMeBQngs-FRyB8Tn9_x9v_yl3QxoTvrgPxwB9nsuIng0zwA01X5fhL7NngrKNwAa_APhQqYI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1528885231</pqid></control><display><type>article</type><title>Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Collins, Allan J., MD ; Monda, Keri L., PhD ; Molony, Julia T., MS ; Li, Suying, PhD ; Gilbertson, David T., PhD ; Bradbury, Brian D., DSc</creator><creatorcontrib>Collins, Allan J., MD ; Monda, Keri L., PhD ; Molony, Julia T., MS ; Li, Suying, PhD ; Gilbertson, David T., PhD ; Bradbury, Brian D., DSc</creatorcontrib><description><![CDATA[Background Changes in anemia management practices due to concerns about erythropoiesis-stimulating agent safety and Medicare payment changes may increase patient risk of transfusion. We examined anemia management trends in hemodialysis patients and risk of red blood cell (RBC) transfusion according to dialysis facility–level hemoglobin concentration. Study Design Retrospective follow-up study; 6-month study period (January to June), 3-month exposure/follow-up. Setting & Participants For each year in 2007-2011, annual cohorts of point-prevalent Medicare primary payer patients receiving hemodialysis on January 1 with one or more hemoglobin measurements during the study period. Annual cohorts averaged 170,000 patients, with 130,000 patients and 3,100 facilities for the risk analysis. Predictor Percentage of facility patient-months with hemoglobin level < 10 g/dL. Outcome Patient-level RBC transfusion rates. Measurements Monthly epoetin alfa and intravenous iron doses, mean hemoglobin levels, and RBC transfusion rates; percentage of facility patient-months with hemoglobin levels < 10 g/dL (exposure) and patient-level RBC transfusion rates (follow-up). Results Percentages of patients with hemoglobin levels < 10 g/dL increased every year from 2007 (6%) to 2011 (∼11%). Epoetin alfa doses, iron doses, and transfusion rates remained relatively stable through 2010 and changed in 2011. Median monthly epoetin alfa and iron doses decreased 25% and 43.8%, respectively, and monthly transfusion rates increased from 2.8% to 3.2% in 2011, a 14.3% increase. Patients in facilities with the highest prevalence of hemoglobin levels < 10 g/dL over 3 months were at ∼30% elevated risk of receiving RBC transfusions within the next 3 months (relative risk, 1.28; 95% CI, 1.22-1.34). Limitations Possibly incomplete claims data; smaller units excluded; hemoglobin levels reported monthly for patients receiving epoetin alfa; transfusions usually not administered in dialysis units. Conclusions Dialysis facility treatment practices, as assessed by percentage of patient-months with hemoglobin levels < 10 g/dL over 3 months, were associated significantly with risk of transfusions in the next 3 months for all patients in the facility, regardless of patient case-mix.]]></description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2013.10.052</identifier><identifier>PMID: 24315770</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Anemia ; Anemia - drug therapy ; Anemia - epidemiology ; Anemia - etiology ; Anemias. Hemoglobinopathies ; Biological and medical sciences ; Diseases of red blood cells ; end-stage renal disease ; Epoetin Alfa ; Erythrocyte Transfusion - statistics &amp; numerical data ; Erythropoietin - therapeutic use ; Female ; Hematinics - therapeutic use ; Hematologic and hematopoietic diseases ; hemodialysis ; hemoglobin concentration ; Hemoglobins - analysis ; Humans ; Insurance Coverage ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Male ; Medical sciences ; Medicare ; Middle Aged ; Nephrology ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Recombinant Proteins - therapeutic use ; red blood cell transfusion ; Renal Dialysis ; Renal failure ; Retrospective Studies ; Risk Assessment ; United States</subject><ispartof>American journal of kidney diseases, 2014-06, Vol.63 (6), p.997-1006</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2014 National Kidney Foundation, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-bf74f9bd9f96f6bf396d9c42b293dcad5e6ccb296396d6395bb38e0f235311d33</citedby><cites>FETCH-LOGICAL-c507t-bf74f9bd9f96f6bf396d9c42b293dcad5e6ccb296396d6395bb38e0f235311d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0272638613014352$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=28538757$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24315770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Collins, Allan J., MD</creatorcontrib><creatorcontrib>Monda, Keri L., PhD</creatorcontrib><creatorcontrib>Molony, Julia T., MS</creatorcontrib><creatorcontrib>Li, Suying, PhD</creatorcontrib><creatorcontrib>Gilbertson, David T., PhD</creatorcontrib><creatorcontrib>Bradbury, Brian D., DSc</creatorcontrib><title>Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description><![CDATA[Background Changes in anemia management practices due to concerns about erythropoiesis-stimulating agent safety and Medicare payment changes may increase patient risk of transfusion. We examined anemia management trends in hemodialysis patients and risk of red blood cell (RBC) transfusion according to dialysis facility–level hemoglobin concentration. Study Design Retrospective follow-up study; 6-month study period (January to June), 3-month exposure/follow-up. Setting & Participants For each year in 2007-2011, annual cohorts of point-prevalent Medicare primary payer patients receiving hemodialysis on January 1 with one or more hemoglobin measurements during the study period. Annual cohorts averaged 170,000 patients, with 130,000 patients and 3,100 facilities for the risk analysis. Predictor Percentage of facility patient-months with hemoglobin level < 10 g/dL. Outcome Patient-level RBC transfusion rates. Measurements Monthly epoetin alfa and intravenous iron doses, mean hemoglobin levels, and RBC transfusion rates; percentage of facility patient-months with hemoglobin levels < 10 g/dL (exposure) and patient-level RBC transfusion rates (follow-up). Results Percentages of patients with hemoglobin levels < 10 g/dL increased every year from 2007 (6%) to 2011 (∼11%). Epoetin alfa doses, iron doses, and transfusion rates remained relatively stable through 2010 and changed in 2011. Median monthly epoetin alfa and iron doses decreased 25% and 43.8%, respectively, and monthly transfusion rates increased from 2.8% to 3.2% in 2011, a 14.3% increase. Patients in facilities with the highest prevalence of hemoglobin levels < 10 g/dL over 3 months were at ∼30% elevated risk of receiving RBC transfusions within the next 3 months (relative risk, 1.28; 95% CI, 1.22-1.34). Limitations Possibly incomplete claims data; smaller units excluded; hemoglobin levels reported monthly for patients receiving epoetin alfa; transfusions usually not administered in dialysis units. Conclusions Dialysis facility treatment practices, as assessed by percentage of patient-months with hemoglobin levels < 10 g/dL over 3 months, were associated significantly with risk of transfusions in the next 3 months for all patients in the facility, regardless of patient case-mix.]]></description><subject>Aged</subject><subject>Anemia</subject><subject>Anemia - drug therapy</subject><subject>Anemia - epidemiology</subject><subject>Anemia - etiology</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Biological and medical sciences</subject><subject>Diseases of red blood cells</subject><subject>end-stage renal disease</subject><subject>Epoetin Alfa</subject><subject>Erythrocyte Transfusion - statistics &amp; numerical data</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Hematinics - therapeutic use</subject><subject>Hematologic and hematopoietic diseases</subject><subject>hemodialysis</subject><subject>hemoglobin concentration</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Insurance Coverage</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicare</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>red blood cell transfusion</subject><subject>Renal Dialysis</subject><subject>Renal failure</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>United States</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUuLFDEQgIMo7rj6BzxIXwQvPeYxSadBBBl3XWFA0fXgKaTzkPT0dNZU98L8e6uZUcGDEBJS9VUlfEXIc0bXjErxul_bfu_XnDKBgTWV_AFZMclFrbTQD8mK8obXSmh1QZ4A9JTSVij1mFzwjWCyaeiKfL-KMbipyrG6ti4NaTrWu3AfhuomHPKPIXdprLZ5dGGcip1SHitc75MdjpCg-owhzFRfEuyXHrfFjhBnQO4peRTtAOHZ-bwk366vbrc39e7Th4_bd7vaSdpMdRebTWw738ZWRdVF0Srfug3veCu8s14G5Rxe1JLATXad0IFGLqRgzAtxSV6d-t6V_HMOMJlDAheGwY4hz2BQiNYarTBE-Ql1JQOUEM1dSQdbjoZRsyg1vVmUmkXpEkOlWPTi3H_uDsH_KfntEIGXZ8CCs0NEBS7BX05LoRvZIPfmxAW0cZ9CMeBQngs-FRyB8Tn9_x9v_yl3QxoTvrgPxwB9nsuIng0zwA01X5fhL7NngrKNwAa_APhQqYI</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Collins, Allan J., MD</creator><creator>Monda, Keri L., PhD</creator><creator>Molony, Julia T., MS</creator><creator>Li, Suying, PhD</creator><creator>Gilbertson, David T., PhD</creator><creator>Bradbury, Brian D., DSc</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion</title><author>Collins, Allan J., MD ; Monda, Keri L., PhD ; Molony, Julia T., MS ; Li, Suying, PhD ; Gilbertson, David T., PhD ; Bradbury, Brian D., DSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-bf74f9bd9f96f6bf396d9c42b293dcad5e6ccb296396d6395bb38e0f235311d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Anemia</topic><topic>Anemia - drug therapy</topic><topic>Anemia - epidemiology</topic><topic>Anemia - etiology</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Biological and medical sciences</topic><topic>Diseases of red blood cells</topic><topic>end-stage renal disease</topic><topic>Epoetin Alfa</topic><topic>Erythrocyte Transfusion - statistics &amp; numerical data</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Hematinics - therapeutic use</topic><topic>Hematologic and hematopoietic diseases</topic><topic>hemodialysis</topic><topic>hemoglobin concentration</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Insurance Coverage</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicare</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>red blood cell transfusion</topic><topic>Renal Dialysis</topic><topic>Renal failure</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Collins, Allan J., MD</creatorcontrib><creatorcontrib>Monda, Keri L., PhD</creatorcontrib><creatorcontrib>Molony, Julia T., MS</creatorcontrib><creatorcontrib>Li, Suying, PhD</creatorcontrib><creatorcontrib>Gilbertson, David T., PhD</creatorcontrib><creatorcontrib>Bradbury, Brian D., DSc</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Collins, Allan J., MD</au><au>Monda, Keri L., PhD</au><au>Molony, Julia T., MS</au><au>Li, Suying, PhD</au><au>Gilbertson, David T., PhD</au><au>Bradbury, Brian D., DSc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>63</volume><issue>6</issue><spage>997</spage><epage>1006</epage><pages>997-1006</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract><![CDATA[Background Changes in anemia management practices due to concerns about erythropoiesis-stimulating agent safety and Medicare payment changes may increase patient risk of transfusion. We examined anemia management trends in hemodialysis patients and risk of red blood cell (RBC) transfusion according to dialysis facility–level hemoglobin concentration. Study Design Retrospective follow-up study; 6-month study period (January to June), 3-month exposure/follow-up. Setting & Participants For each year in 2007-2011, annual cohorts of point-prevalent Medicare primary payer patients receiving hemodialysis on January 1 with one or more hemoglobin measurements during the study period. Annual cohorts averaged 170,000 patients, with 130,000 patients and 3,100 facilities for the risk analysis. Predictor Percentage of facility patient-months with hemoglobin level < 10 g/dL. Outcome Patient-level RBC transfusion rates. Measurements Monthly epoetin alfa and intravenous iron doses, mean hemoglobin levels, and RBC transfusion rates; percentage of facility patient-months with hemoglobin levels < 10 g/dL (exposure) and patient-level RBC transfusion rates (follow-up). Results Percentages of patients with hemoglobin levels < 10 g/dL increased every year from 2007 (6%) to 2011 (∼11%). Epoetin alfa doses, iron doses, and transfusion rates remained relatively stable through 2010 and changed in 2011. Median monthly epoetin alfa and iron doses decreased 25% and 43.8%, respectively, and monthly transfusion rates increased from 2.8% to 3.2% in 2011, a 14.3% increase. Patients in facilities with the highest prevalence of hemoglobin levels < 10 g/dL over 3 months were at ∼30% elevated risk of receiving RBC transfusions within the next 3 months (relative risk, 1.28; 95% CI, 1.22-1.34). Limitations Possibly incomplete claims data; smaller units excluded; hemoglobin levels reported monthly for patients receiving epoetin alfa; transfusions usually not administered in dialysis units. Conclusions Dialysis facility treatment practices, as assessed by percentage of patient-months with hemoglobin levels < 10 g/dL over 3 months, were associated significantly with risk of transfusions in the next 3 months for all patients in the facility, regardless of patient case-mix.]]></abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>24315770</pmid><doi>10.1053/j.ajkd.2013.10.052</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0272-6386
ispartof American journal of kidney diseases, 2014-06, Vol.63 (6), p.997-1006
issn 0272-6386
1523-6838
language eng
recordid cdi_proquest_miscellaneous_1528885231
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Anemia
Anemia - drug therapy
Anemia - epidemiology
Anemia - etiology
Anemias. Hemoglobinopathies
Biological and medical sciences
Diseases of red blood cells
end-stage renal disease
Epoetin Alfa
Erythrocyte Transfusion - statistics & numerical data
Erythropoietin - therapeutic use
Female
Hematinics - therapeutic use
Hematologic and hematopoietic diseases
hemodialysis
hemoglobin concentration
Hemoglobins - analysis
Humans
Insurance Coverage
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - therapy
Male
Medical sciences
Medicare
Middle Aged
Nephrology
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Recombinant Proteins - therapeutic use
red blood cell transfusion
Renal Dialysis
Renal failure
Retrospective Studies
Risk Assessment
United States
title Effect of Facility-Level Hemoglobin Concentration on Dialysis Patient Risk of Transfusion
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T17%3A18%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Facility-Level%20Hemoglobin%20Concentration%20on%20Dialysis%20Patient%20Risk%20of%20Transfusion&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Collins,%20Allan%20J.,%20MD&rft.date=2014-06-01&rft.volume=63&rft.issue=6&rft.spage=997&rft.epage=1006&rft.pages=997-1006&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2013.10.052&rft_dat=%3Cproquest_cross%3E1528885231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1528885231&rft_id=info:pmid/24315770&rft_els_id=S0272638613014352&rfr_iscdi=true